Search

Home > Diabetes Knowledge into Practice Podcast > Introducing injectable therapies | With Dr Ronald Goldenberg


	Podcast:		Diabetes Knowledge into Practice Podcast
	Episode:		Introducing injectable therapies \| With Dr Ronald Goldenberg
	Category:		Health
	Duration:		00:13:39
	Publish Date:		2021-10-12 04:00:00
	Description:		Clinical inertia in type 2 diabetes is particularly pronounced for injectable agents, with delays of 6-8 years reported to move from oral agents to insulin therapy. This can be a result of many barriers at both the patient and clinician level, from perceptions of injectable agents to lack of time to provide sufficient education. Join Dr Ronald Goldenberg for a discussion of how to overcome these barriers to initiating injectable therapy. We’ve got a new website! Find it at diabetes.knowledgeintopractice.com, where you can see all past episodes of the podcast as well as other free CME resources. Follow us on Twitter (@dkipractice) or connect on LinkedIn. Disclosures: Dr Ronald Goldenberg discloses the following: Speakers fees, Research fees, Consultant fees: AZ, BI, Merck, Lilly, Janssen, NovoNordisk, Sanofi All conflicts of interest have been mitigated prior to this activity. References: Okemah J, et al. Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review. Adv Ther. 2018 Nov;35(11):1735-1745. Paul SK, et al. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015 Aug 7;14:100. Target Audience This educational activity is intended for an international audience of non-US and non-UK HCPs. Funding Statement This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.
	Total Play:		0